Phase 4 N=75 Clinical and Imaging Trial of Uridine for Veterans With Suicidal Ideation
Suicidal Ideation
Primary: Change From Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS) — 13.69; 14.46; 8.27; 10.87 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=6 A New Heat Therapy Device for Home-based Leg Heating in Patients With Lower-extremity Peripheral Artery Disease
Peripheral Arterial Disease · Intermittent Claudication
Primary: Change in Six-minute Walk Distance — 32.3 Meters
Phase 2 N=116 Study Will Assess the Safety, Neutralizing Activity and Efficacy of AZD3152 in Adults With Conditions Increasing Risk of Inadequate Protective Immune Response After Vaccination and Thus Are at High Risk of Developing Severe COVID-19
COVID-19, SARS-CoV-2
Primary: The Number and Proportion of Subjects With AEs, SAEs, MAAEs, AESIs. — 45; 17; 5; 2 Participants
Phase 2 N=76 ALPN-101 (Acazicolcept) in Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
Primary: Safety and Tolerability as Assessed by Number of Participants With Treatment- Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 23; 24; 2; 2 Participants
Phase 3 N=397 Safety and Effectiveness Evaluation of the Multi-Electrode Radiofrequency Balloon Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation
Atrial Fibrillation
Primary: Number of Participants With Any Primary Adverse Events (PAE) That Occurred Within 7 Days Following Atrial Fibrillation (AF) Ablation Procedure Using HELIOSTAR Catheter…
Phase 1 N=26 Study Comparing Once Daily Dose of 900mg of TETA 4HCL Against Cuprior® (450mg Trientine Base, Twice Daily).
Wilson's Disease
Primary: Plasma Concentrations (AUC) of TETA 4HCL Following Administration of Two TETA 4HCL Tablet Formulations. — 12668.493; 10971.720; 13561.621; 11778.232 h*ng/mL
N/A N=150 Haploidentical CD34+ Selected Cells Combined With Single Unit Umbilical Cord Blood Transplant for Treatment of High-risk Hematologic Disorders
Hematologic Disorders
Primary: The Number of Patients With Successful Engraftment — 144 Participants
N/A N=9 BRAIN, Symptoms, and Physical Activity in COPD
COPD · Chronic Musculoskeletal Pain
Primary: Cortical Thickness — 2.2 mm
N/A N=80 Volatilome and Single-Lead Electrocardiogram Optimize Ischemic Heart Disease Diagnosis Using Machine Learning Models
Coronary Artery Disease · Ischemic Heart Disease · Chronic Coronary Disease
Primary: Diagnostic Accuracy (AUC, Sensitivity, Specificity, NPV, PPV) of the Stress-ECG Test in Ischemic Heart Disease — 0.507; 0.507; 0.484; 0.484 Proportion probability
N/A N=1,260 A Community-based Assessment of Skin Care, Allergies, and Eczema
Atopic Dermatitis · Atopic Disorders · Eczema
Primary: Provider-diagnosed Atopic Dermatitis — 217.7; 268.5 Participants with imputed values — p=0.019
Phase 2 N=30 Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer
Resectable Cholangiocarcinoma · Stage IB Intrahepatic Cholangiocarcinoma AJCC v8 · Stage II Intrahepatic Cholangiocarcinoma AJCC v8
Primary: Number of Participants Who Completed All Preoperative and Operative Therapy — 22 Participants
N/A N=93,476 INSPIRE Trial for Abdominal Infections
Abdominal (ABD) Infection
Primary: Extended-Spectrum Days of Antibacterial Therapy (ES-DOT) Per Empiric Day — 68616; 68679; 76605; 50001 Extended-Spectrum Days-of-Therapy
Phase 3 N=420 Active-control Randomized Trial Comparing 4-factor Prothrombin Complex Concentrate With Frozen Plasma in Cardiac Surgery
Bleeding Cardiac Surgery Patients
Primary: Number of Patients Requiring Additional Hemostatic Intervention — 166; 125; 47; 82 Participants — p=<0.0001
Phase 2 N=74 Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer
Anatomic Stage III Breast Cancer AJCC v8 · Anatomic Stage IV Breast Cancer AJCC v8 · Locally Advanced Breast Carcinoma
Primary: Number of Subject With Overall Response — 15; 3; 8 Participants
Phase 3 N=68 A Clinical Trial Utilizing Dantrolene in Patients With Ventricular Arrhythmias.
Ventricular Tachycardia
Primary: Number of Participants With Inducible Sustained Ventricular Tachycardia/ Ventricular Fibrillation (VT/VF) Utilizing Standardized Stimulation Protocol. — 4; 9 Participants